drugset / Trial / NCT03181386

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

NCT03181386

Phase 3 Completed 60 enrolled University of Sao Paulo General Hospital
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this study is to evaluate the safety of a protocol which does not suspend the new oral anticoagulants (dabigatran, rivaroxaban and apixaban) in front of dental extractions in patients with non-valvular atrial fibrillation.

Timeline

Start
2017-05-03
Primary completion
2020-11-30
Completion
2022-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral
Subject Apixaban Small molecule 5 mg Oral
Subject Dabigatran Unknown 110 mg Oral
Subject Dabigatran Unknown 150 mg Oral
Subject Rivaroxaban Other / unclassified 15 mg Oral
Subject Rivaroxaban Other / unclassified 20 mg Oral
Comparator Warfarin Small molecule